What is the primary goal of ICH E6 in clinical research?

The primary goal of ICH E6 is to support marketing applications for drugs. This guideline is focused on ensuring the safety, quality, and efficacy of pharmaceuticals, which is crucial for regulatory submissions and approvals in the drug development process. By providing a framework for Good Clinical Practice (GCP), ICH E6 emphasizes the need for high standards in the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials.

This ensures that the data generated is reliable and can be used to demonstrate to regulatory authorities that a drug is safe and effective for its intended use. It underlines the importance of protecting the rights, integrity, and confidentiality of study participants, while also providing guidelines that make it easier to create marketing applications with well-supported evidence derived from rigorously conducted clinical trials.

Establishing new drug pricing, designing marketing strategies, and conducting only observational studies are not the primary focus of ICH E6. Instead, they relate to broader aspects of drug commercialization and research methodologies that do not directly align with the specific aims of ensuring regulatory compliance for drug applications outlined in this guideline.